What Is Sezime (Hibemib) Tablet Used For, and Which Patients with Hyperlipidemia Should Take It?

Sezime® (hibemichol) tablets represent a novel therapeutic option for managing hypercholesterolemia, particularly in patients with elevated low-density lipoprotein cholesterol (LDL-C). Hibemichol is a selective intestinal cholesterol absorption inhibitor that acts by targeting the Niemann-Pick C1-like 1 (NPC1L1) protein—a key transporter responsible for dietary and biliary cholesterol uptake in the proximal small intestine. By blocking NPC1L1, hibemichol reduces cholesterol absorption, leading to compensatory upregulation of hepatic LDL receptors and subsequent clearance of circulating LDL-C.

This mechanism distinguishes hibemichol from statins (which inhibit HMG-CoA reductase) and ezetimibe (a first-generation NPC1L1 inhibitor), offering a complementary or alternative approach for patients who are statin-intolerant, inadequately controlled on maximally tolerated statin therapy, or require additional LDL-C lowering to meet guideline-recommended targets—especially those with established atherosclerotic cardiovascular disease (ASCVD), familial hypercholesterolemia, or diabetes mellitus.

Clinical evidence supports hibemichol’s efficacy as monotherapy and in combination with statins, demonstrating consistent LDL-C reductions of approximately 15–25% beyond background statin therapy. Its favorable safety profile—including low rates of muscle-related adverse events and no clinically significant drug–drug interactions with commonly prescribed cardiovascular medications—makes it especially suitable for older adults and individuals with polypharmacy. As with all lipid-lowering agents, treatment decisions should be individualized based on cardiovascular risk assessment, baseline lipid parameters, tolerability history, and adherence considerations.